Landos Biopharma, Inc.: Nasdaq/NYSE listing notice — Landos Biopharma gets Nasdaq approval to transfer to Capital Market; 180-day bid price compliance extension

Landos Biopharma, Inc.

Transfer from Nasdaq Global Market to Nasdaq Capital Market effective Dec 15, 2022.
Additional 180-day compliance period granted until June 12, 2023 to meet $1.00 minimum bid price.
Company may effect a reverse stock split to cure the bid price deficiency if necessary.
Failure to regain compliance could result in delisting, subject to appeal to a Nasdaq hearings panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Landos Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

The Company intends to actively monitor the bid price of its common stock and will consider available options, including a reverse stock split, to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Landos Biopharma, Inc.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-22-026636

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.